Annual Report along with annexure for FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Clinitech Laboratory Ltd, a healthcare diagnostics company, filed its 15th Annual Report for FY 2024-25, marking its first full year as a BSE-listed entity after its SME IPO in August 2024. Total revenue grew to INR 846.27 lakhs from INR 643.92 lakhs (up ~31%), while net profit after tax rose modestly to INR 39.47 lakhs from INR 37.12 lakhs (up ~6%). EPS dipped to INR 1.90 from INR 2.37 due to the expanded share base post-IPO. The board has not recommended any dividend, citing the need to conserve resources for growth. Key highlights include opening new branches at Ulhasnagar and New Panvel, a tie-up with Crystal Care Hospital, and the company becoming loan-free during the year.
For shareholders, the report shows healthy top-line growth driven by expansion, though bottom-line growth was modest as costs scaled up faster. The IPO proceeds and debt-free status provide a strong base for future growth, but the absence of dividend means returns will depend on capital appreciation. The September 23 AGM will see the re-appointment of the Managing Director and an alteration of Articles of Association to enable full dematerialization of shares.